BIOVAXYS ANNOUNCES CONVERSION OF DEBENTURES AND GRANT OF STOCK OPTIONS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 20 2025
0mins
Should l Buy ?
Source: PRnewswire
Debenture Conversion Announcement: BioVaxys Technology Corp. has announced the conversion of $25,000 in outstanding unsecured convertible debentures into common shares, resulting in the issuance of 148,468 shares at a conversion price of $0.17 per share, with the transaction involving insider James Passin, the CEO.
Stock Options Granted: The company has granted 550,000 stock options to directors, officers, and employees, each convertible into a share at an exercise price of $0.25, with a vesting schedule over the next year, subject to regulatory approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
